Cipla to be listed in Dow Jones Sustainability Index for emerging markets
Mumbai: Cipla Limited has recently announced that the company has been selected in the S&P Dow Jones Sustainability Index (DJSI) for the Emerging Markets for 2021.
The DJSI family of indices is operated by S&P Dow Jones. The Emerging Markets Index for the year comprises of 108 companies from 12 emerging economies, including China, Brazil, South Africa and Taiwan. Created jointly by S&P Dow Jones Indices and SAM, the DJSI is the gold standard for corporate sustainability, and is highly regarded by global investors and financial analysts looking at ESGbased investments.
The selection process included the world's largest ~4000 listed companies, which underwent a rigorous assessment on Economic & Governance, Social & Environmental parameters such as corporate governance, ethics, risk management, climate change mitigation, stakeholder engagement, access to medicine, quality, corporate social responsibility and human resource practices.
As of November 12, 2021, Cipla performed in the top decile in the pharmaceutical Industry in the S&P Global Corporate Sustainability Assessment, with a ranking of 93 percentile in the industry, meaning 93% of companies reached an equal or lower ESG Score. The Company significantly improved performance in parameters like strategy to improve access to drugs or products, human capital development, tax strategy and climate strategy compared to last year.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.